Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.19 is 72% above its 5-year average of -0.67, near the high end of its 5-year range (-0.86–-0.19).
67.52% above its 12-month average of -0.58.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.04.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 20 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.19
EARNINGS PER SHARE (EPS) AVG TTM
-0.58
EARNINGS PER SHARE (EPS) AVG 3Y
-0.69
EARNINGS PER SHARE (EPS) AVG 5Y
-0.67
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+67.52%
CURRENT VS 3Y AVG
+72.56%
CURRENT VS 5Y AVG
+71.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cognition Therapeutics, Inc.
Market Cap
$84.13M
Earnings Per Share (EPS)
-0.19
TTM Avg
-0.58
3Y Avg
-0.69
5Y Avg
-0.67
Market Cap
$84.00M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.76
3Y Avg
-0.68
5Y Avg
-1.48
Market Cap
$88.97M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.79M
Earnings Per Share (EPS)
-1.18
TTM Avg
-4.40
3Y Avg
-32.48
5Y Avg
-54.06
Market Cap
$85.60M
Earnings Per Share (EPS)
-1.88
TTM Avg
-2.06
3Y Avg
-2.07
5Y Avg
-1.66
Market Cap
$87.96M
Earnings Per Share (EPS)
0.07
TTM Avg
-0.09
3Y Avg
-1.24
5Y Avg
-1.25
Market Cap
$79.78M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.32
3Y Avg
-0.23
5Y Avg
-0.23
Market Cap
$88.63M
Earnings Per Share (EPS)
-0.60
TTM Avg
-0.82
3Y Avg
-0.86
5Y Avg
-0.88
Market Cap
$88.21M
Earnings Per Share (EPS)
0.08
TTM Avg
-0.19
3Y Avg
-0.36
5Y Avg
-0.27
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $84.13M | -0.19 | -0.58 | -0.69 | -0.67 |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -0.51 | -0.76 | -0.68 | -1.48 |
| Conexeu Sciences Inc. (CNXU)vs › | $88.97M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.79M | -1.18 | -4.40 | -32.48 | -54.06 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | -1.88 | -2.06 | -2.07 | -1.66 |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 0.07 | -0.09 | -1.24 | -1.25 |
| Citius Oncology, Inc. (CTOR)vs › | $79.78M | -0.48 | -0.32 | -0.23 | -0.23 |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | -0.60 | -0.82 | -0.86 | -0.88 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 0.08 | -0.19 | -0.36 | -0.27 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -1.17 | -2.88 | -6.48 | -4.74 |
Trailing EPS (TTM)
$-0.19
Forward EPS (Est.)
$-0.30
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.32 |
| 2024-12-31 | -0.85 |
| 2023-12-31 | -0.86 |
| 2022-12-31 | -0.74 |
| 2021-12-31 | -0.73 |
| 2020-12-31 | -0.55 |
| 2019-12-31 | -0.32 |
